FDA Archives - Page 88 of 220

3 minute read

Altamira Therapeutics Announces Publication Of Results From Phase 2 Trial With AM-125 In Acute Vestibular Syndrome In Leading Peer Reviewed Journal

April 12, 9:32 AM

Detailed results from TRAVERS trial addressing acute vestibular syndrome with AM-125 (intranasal betahistine) published in Otology & Neurotology Study demonstrates proof of concept and shows good

CYTO

2 minute read

MyMD Pharmaceuticals Provides Dosing Update On Phase 2 Multi-Center Clinical Trial Of MYMD-1 As A Therapy For Delaying Aging And Extending Healthy Lifespan

By Happy Mohamed

April 12, 8:37 AM

- Currently, there are no FDA-approved treatments for sarcopenia/frailty - - MyMD is only 3 patients away from dosing its final patient in its first Phase 2 clinical trial of lead drug candidate

MYMD

2 minute read

INOVIO Announces Acceptance Of Abstract For Oral Presentation On INO-4201 As An Ebola Booster For rVSV-ZEBOV At ECCMID 2023

By Happy Mohamed

April 12, 8:13 AM

Immunological data from recently completed Phase 1b trial will be presented on April 16th PLYMOUTH MEETING, Pa., April 12, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company

INO

2 minute read

Aurinia Pharmaceuticals Announces New And Refined Method Of Use Patent For LUPKYNIS In The Treatment Of Lupus Nephritis Issued By United States Patent And Trademark Office

By Happy Mohamed

April 11, 10:27 AM

New method of use patent (U.S. Patent No. 11,622,991) issued for LUPKYNIS Reflects the unique and proprietary dosing regimen indicated for LUPKINIS in Lupus Nephritis Announcement is a follow-up to previously announced

AUPH

2 minute read

Avalon GloboCare Signs Agreement With Qi Diagnostics To Exclusively Distribute KetoAir Breathalyzer Device And AI-Enabled Software In North America, South America, U.K. And European Union

By Happy Mohamed

April 11, 9:01 AM

Commercialization-ready; initially targeting diabetes reversal and weight management markets Coupling diagnostic tools with advanced artificial intelligence software for nutrition management FREEHOLD, N.J.,

ALBT

4 minute read

Veru Announces Preclinical Study Results That Demonstrate Sabizabulin Inhibits Poxviruses

By Happy Mohamed

April 11, 8:33 AM

Sabizabulin inhibited the cell release and cell-to-cell spread of poxvirus in a preclinical study Veru further expands study of sabizabulin for the treatment of poxvirus acute respiratory distress syndrome

VERU

2 minute read

IN8bio To Present New Clinical Data From Phase 1 Trial Of INB-100 At EBMT 2023 Annual Meeting

By Happy Mohamed

April 11, 8:19 AM

Updated data on durability of responses and long-term complete responses (CRs) in leukemia patients treated with INB-100 will be presented; no dose-limiting toxicities have been observed New correlative

INAB

4 minute read

Teva To Present New Data On Once-Daily AUSTEDO XR Extended-Release Tablets At The 2023 American Academy Of Neurology Annual Meeting

By Happy Mohamed

April 11, 8:14 AM

Dose proportionality and bioequivalence studies demonstrate once-daily AUSTEDO XR is therapeutically equivalent to twice-daily AUSTEDO®(deutetrabenazine) tablets The U.S. Food and Drug Administration (FDA)

TEVA

3 minute read

Reported Late Monday April 10, Foghorn Therapeutics To Present Preclinical Data From Its Selective CBP And EP300 Protein Degrader Programs And Preclinical Data For FHD-286, A Selective Inhibitor Of BRG1 And BRM At AACR April 14-19 2023

By Happy Mohamed

April 11, 12:33 AM

Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that

FHTX